Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy does cause nausea and other gastrointestinal side effects in many people, particularly in the first few weeks of treatment or after a dose increase. These reactions are real, common, and well-documented in clinical trials — but for most people they are temporary, manageable, and far less severe than the initial worry suggests. Wegovy is a prescription-only medicine (semaglutide, made by Novo Nordisk) that requires clinical assessment before it can be prescribed; a prescriber will weigh up these effects alongside your individual health picture before recommending it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
One of the most common things our prescribers hear is this: a patient feels nauseated in their first few weeks, assumes something has gone wrong, and considers stopping treatment. The reality is almost the opposite. Nausea at the start is a sign that semaglutide is doing what it is supposed to do. It slows gastric emptying (the speed at which food moves from the stomach into the small intestine) and that process directly reduces appetite. The stomach noticing a change is expected, not alarming.
The STEP 1 clinical trial, which assessed semaglutide 2.4mg across 68 weeks in adults with obesity, found that most gastrointestinal side effects clustered in the early weeks and then declined as participants' bodies adjusted. Stopping at week two because of nausea would mean missing the point at which the medicine typically begins to feel more comfortable. That said, if symptoms are severe, persistent or feel wrong in any way, the right move is to contact your prescribing team, not to push through alone. Our support team is available seven days a week for exactly this kind of question.
You can read the full NHS patient guidance on semaglutide's side effect profile on the NHS semaglutide medicines page, which gives a clear breakdown of common, uncommon and rare effects.
Semaglutide activates GLP-1 receptors in the gut and brain. In the gut, one effect is that the valve between the stomach and small intestine relaxes more slowly, so food stays in the stomach longer. That fuller feeling is part of why appetite reduces, but it also means the stomach has more time to signal discomfort, especially early on or after a dose step.
The effects people report most often are nausea, burping, constipation, diarrhoea, reflux and indigestion. These can overlap or alternate. Some people find one dominates; others cycle between a couple. If burping is the main issue, it often reflects air being swallowed along with larger meals, slowing down at the table tends to help. Fatigue is also reported, particularly in the early weeks, and if low energy is becoming a persistent problem, our Wegovy fatigue solution guide covers practical steps that can help.
A quick habit worth building: before your injection each week, spend sixty seconds reviewing how the previous week felt, any nausea, changes in digestion, energy. Noting a pattern makes it much easier to have a useful conversation with your prescriber at review, and it helps distinguish normal adjustment from something that warrants attention.
For a broader look at the full picture, our Wegovy side effects page covers both common and less common effects in more detail.
Most sickness on Wegovy is mild to moderate and time-limited. But there are patterns that need prompt medical attention rather than watchful waiting.
Severe, persistent stomach pain (especially pain that radiates through to your back) with or without vomiting should not be managed at home. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known infrequent risk with GLP-1 medicines, including semaglutide. The MHRA's Yellow Card scheme allows patients and carers to report suspected side effects, and doing so helps build the evidence base around these medicines for everyone.
Other reasons to contact a healthcare professional promptly: repeated vomiting that stops you keeping fluids down (dehydration is a real risk), signs of an allergic reaction, or symptoms that are getting worse rather than staying steady or improving after the first couple of weeks. Eating too much in one sitting (which is easier to do by accident than it sounds) can intensify nausea significantly. What happens when you overeat on Wegovy is worth understanding before it catches you out.
These medicines are prescription-only for good reason. The clinical review that comes with a legitimate prescription is there precisely to catch complications early and adjust the plan if needed. Private treatment through a GPhC-registered pharmacy like ours includes that review at every stage, not just at the start.
The clinical consensus, reflected across NHS guidance and the prescribing notes in semaglutide's Summary of Product Characteristics, points to a few consistent strategies. Smaller portions, eaten slowly, reduce the workload on a stomach that is already emptying more slowly. Fatty or very rich food is harder to process under these conditions, cutting back on the most obvious culprits on injection day and the day after is a simple starting point. Staying well hydrated matters, especially if diarrhoea is also present.
Some people find timing their injection in the evening means the worst of any nausea has passed by morning; others prefer morning injections. There is no single right answer, it is worth experimenting under prescriber guidance. If nausea is consistent and affecting your quality of life rather than easing over time, that is exactly the kind of conversation to have at your clinical review. The underlying reason semaglutide causes nausea and what tends to help is covered in more depth separately.
If you are weighing up whether these side effects are manageable for you personally, or whether treatment might suit your situation, checking your eligibility with our prescribers is the right next step. The consultation is free, and a real clinician (not an automated system) reads your answers and gives you a clear picture of what to expect.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.